Pediatric tumefactive multiple sclerosis case (with baló-like lesions), diagnostic and treatment challenges

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with an incidence of 0.2–2.9 per 100,000 children worldwide, of which 0.3% are younger than 10 years at diagnosis¹. Tumefactive MS (TMS) and Baló’s concentric sclerosis are rarely referred in the literature of MS variants. They are challenging to diagnose and treat situations that should usually be differentiated from brain tumors, especially in children^2,3.

We present a 7.5-year-old boy with TMS and a Baló-like lesion who initially presented with subacute right hemiparesis, ipsilateral facial palsy, and an otherwise unremarkable personal and family history. Brain magnetic resonance imaging (MRI) revealed three tumefactive (over 2 cm) periventricular lesions. One tumefactive lesion exhibited a concentric ring appearance, an open ring diffusion restriction pattern, and thin ring enhancement, consistent with a Baló-like lesion (Fig. 1A, 1B). Spinal MRI was normal. Laboratory testing excluded autoimmune diseases and infection (Table 1). The absence of cortical involvement, mass effect, and seizures in combination with the aforementioned lesions at presentation favored the diagnosis of clinically isolated syndrome⁴. The patient was treated with methylprednisolone pulses, intravenous immunoglobulins, and finally showed optimal response to plasmapheresis.

One month later, the patient developed left hemiparesis which gradually evolved into motor disability, while new lesions at the right periventricular white matter (Fig. 1C) and at additional sites were consistent with MS, according to space and time international criteria⁴. Patient responded considerably to a five, every other day, cyclophosphamide infusion scheme of 800 mg/m² body surface area. Despite clinical improvement with mild residual neurological deficit, in view of new lesion development and inconclusive laboratory investigations (Table 1), a brain tumor should have actively been excluded. Magnetic resonance spectroscopy (MRS) revealed elevated β,γ-Glx peaks and a lipid-lactate doublet, which favored the diagnosis of demyelination. Brain biopsy was avoided due to invasiveness and possibility of misleading results⁵. Instead, computed tomography (CT) revealed hypoattenuation at the areas of abnormality (Fig. 1D), excluding cerebral lymphoma and supporting the diagnosis of TMS⁶. New MRI lesions prompted treatment with methylprednisolone pulses which resulted in clinical stability.

At that time, considering the absence of evidence-based guidelines for TMS immunomodulating treatment, appropriate for our patients’ age, a “wait and see” close follow-up approach was chosen^1,2,4. Treatment-free he remained clinically (Extended Disability Status Scale: 1) and radiologically stable for almost 2 years when a large MRI non-enhancing lesion appeared. Meeting age criteria, treatment with fingolimod was immediately initiated, as it was finally approved as an oral therapy for highly active relapsing–remitting forms of MS (RRMS) for children over 10 years (EMA/685570/2018, EMEA/H/C/002202). Patient exhibited excellent tolerance; he is clinically and radiologically stable, 2 years later.

Differential diagnosis from brain tumors is challenging. Brain biopsy is useful⁶ but requires a high level of expertise; otherwise, results may be misleading. Multimodality imaging with MRI, MRS, and CT, along with clinical findings, has a diagnostic accuracy of up to 97%⁵. The absence of cortical involvement, seizures, cerebral mass effect and the relapsing clinical course responding to treatment make the diagnosis of demyelination practically non-questionable.

Regarding treatment, these typical RRMS patients respond to aggressive therapeutic options, like plasmapheresis and cyclophosphamide, as occurred in our patient, and finally require disease-modifying therapy. A 2-year treatment with fingolimod proved an effective and safe treatment choice for this child.

Conclusively, the diagnosis of MS variants should be facilitated by relevant accessible diagnostic tools. Brain biopsy remains an option, although invasive. Immunomodulating therapy, like fingolimod, appears as a safe, effective option for children with newly diagnosed tumefactive RRMS. To our knowledge, this is the first child diagnosed 5 years ago, finally treated with fingolimod, and followed under this treatment up for 2 years, described in the literature.